Patil Sushilkumar, Vhora Imran, Amrutiya Jitendra, Lalani Rohan, Misra Ambikanandan
Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara -390001, Gujarat, INDIA.
Curr Pharm Des. 2015;21(29):4155-73. doi: 10.2174/1381612821666150901095722.
The advent of recombinant DNA technology and computational designing has fueled the emergence of proteins and peptides as a new class of modern therapeutics such as vaccines, antigens, antibodies and hormones. Demand for such therapeutics has increased recently due to their distinct pharmacodynamic characteristics of specificity of action and high potency. However, their potential clinical applications are often hindered by involvement of factors which impact their therapeutic potential negatively. Large size, low permeability, conformational fragility, immunogenicity, metabolic degradation and short half-life results in poor bioavailability and inferior efficacy. These challenges have encouraged researchers to devise strategies for effective delivery of proteins and peptides. Recent advances made in nanotechnology are being sought to overcome aforesaid problems and to offer advantages such as higher drug loading, improved stability, sustained release, amenability for non-parenteral administration and targeting through surface modifications. This review focuses on elaborating the role of nanotechnology based formulations and associated challenges in protein and peptide delivery, their clinical outlook and future perspective.
重组DNA技术和计算机设计的出现推动了蛋白质和肽作为一类新型现代治疗药物的出现,如疫苗、抗原、抗体和激素。由于其独特的药效学特性,即作用特异性和高效能,近年来对这类治疗药物的需求有所增加。然而,它们的潜在临床应用常常受到一些负面影响其治疗潜力的因素的阻碍。大分子尺寸、低渗透性、构象脆弱性、免疫原性、代谢降解和短半衰期导致生物利用度差和疗效不佳。这些挑战促使研究人员设计蛋白质和肽的有效递送策略。人们正在寻求纳米技术的最新进展来克服上述问题,并提供诸如更高的药物负载量、更好的稳定性、持续释放、适合非肠道给药以及通过表面修饰实现靶向等优势。本综述着重阐述基于纳米技术的制剂在蛋白质和肽递送中的作用、相关挑战、临床前景及未来展望。